REVB

+ Watchlist + Portfolio

Revelation Biosciences, Inc.

GridBrain — Sign in

GridSentinel — Sign in

GridAegis — Sign in

Key Metrics

Previous Close: $1.11
52-Week Range: $0.88 – $11.72
Market Cap: $4.26M
P/E (TTM): 0.04
EPS (TTM): 27.03
Dividend Yield: —

Advanced Metrics

Price/Book: 0.42
PEG Ratio: —
Return on Equity: -154.77%
Return on Assets: -78.73%
Gross Margin: 0.00%
Operating Margin: 0.00%
Profit Margin: 0.00%
Current Ratio: 6.21
Debt/Equity: 0.07
Total Debt: $739.92K
Free Cash Flow: $-5.78M
Revenue Growth: —
Earnings Growth: —
Enterprise Value: $-6.48M

REVB Income statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Revenue	$0.00	$0.00	$0.00	$0.00
Research & Development	$5.38M	$4.15M	$3.55M	$4.06M
Selling, General & Admin	$5.49M	$4.51M	$4.43M	$5.01M
Operating Expenses	$10.86M	$8.66M	$7.98M	$9.07M
Operating Income	-$10.86M	-$8.66M	-$7.98M	-$9.07M
EBITDA	-$10.84M	-$8.63M	-$7.95M	-$9.04M
Pretax Income	-$10.83M	-$120.25K	-$15.04M	-$8.91M
Net Income	-$10.83M	-$120.25K	-$15.04M	-$8.91M
Diluted EPS	-91775.84	-101.28	-1052.16	-23.95
Diluted Shares	118	1187	14292	620785

REVB Balance Sheet statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Cash & Equivalents	$5.25M	$11.99M	$6.50M	$10.70M
Current Assets	$5.41M	$12.15M	$6.57M	$10.81M
Total Assets	$5.50M	$12.21M	$6.62M	$11.58M
Current Liabilities	$4.45M	$5.56M	$1.91M	$2.00M
Total Debt	$0.00	—	$0.00	$746.78K
Total Liabilities	$4.45M	$5.56M	$1.91M	$2.72M
Retained Earnings	-$25.35M	-$25.47M	-$40.51M	-$49.42M
Shareholders' Equity	$1.05M	$6.65M	$4.71M	$8.86M
Working Capital	$962.32K	$6.58M	$4.65M	$8.81M

REVB Cash Flow statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Operating Cash Flow	-$11.22M	-$7.29M	-$18.32M	-$8.27M
Capital Expenditure	—	—	-$19.17K	—
Free Cash Flow	-$11.22M	-$7.29M	-$18.34M	-$8.27M
Depreciation & Amortisation	$25.05K	$25.05K	$27.92K	$27.06K
Stock-Based Compensation	$301.12K	$155.72K	$168.85K	$595.37K
Investing Cash Flow	$0.00	$0.00	-$19.17K	$0.00
Financing Cash Flow	$15.20M	$14.03M	$12.85M	$12.47M
Share Repurchases	—	-$5.00K	$0.00	—
Net Change in Cash	$3.98M	$6.74M	-$5.49M	$4.20M

REVB Income statement, quarterly periods, in USD
USD	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026
Revenue	$0.00	$0.00	$0.00	$0.00	$0.00
Research & Development	$858.83K	$1.32M	$922.86K	$964.19K	$1.38M
Selling, General & Admin	$1.24M	$1.14M	$1.02M	$1.61M	$1.72M
Operating Expenses	$2.09M	$2.46M	$1.94M	$2.57M	$3.09M
Operating Income	-$2.09M	-$2.46M	-$1.94M	-$2.57M	-$3.09M
EBITDA	-$2.09M	-$2.45M	-$1.94M	-$2.57M	-$3.09M
Pretax Income	-$2.05M	-$2.44M	-$1.91M	-$2.51M	-$3.01M
Net Income	-$2.05M	-$2.44M	-$1.91M	-$2.51M	-$3.01M
Diluted EPS	-25.32	-84.12	-7.08	-1.65	-2.71
Diluted Shares	80942	66889	661183	1.52M	3.21M

REVB Balance Sheet statement, quarterly periods, in USD
USD	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026
Cash & Equivalents	$3.70M	$5.17M	$12.71M	$10.70M	$14.11M
Current Assets	$3.93M	$5.36M	$12.83M	$10.81M	$14.21M
Total Assets	$3.97M	$5.40M	$12.86M	$11.58M	$15.04M
Current Liabilities	$1.09M	$1.57M	$1.85M	$2.00M	$1.42M
Total Debt	—	—	—	$746.78K	$759.04K
Total Liabilities	$1.09M	$1.57M	$1.85M	$2.72M	$2.06M
Retained Earnings	-$42.56M	-$45.00M	-$46.91M	-$49.42M	-$52.43M
Shareholders' Equity	$2.88M	$3.83M	$11.00M	$8.86M	$12.99M
Working Capital	$2.84M	$3.79M	$10.98M	$8.81M	$12.79M

REVB Cash Flow statement, quarterly periods, in USD
USD	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026
Operating Cash Flow	-$2.79M	-$1.92M	-$1.59M	-$1.97M	-$3.21M
Capital Expenditure	—	—	—	—	-$71.88K
Free Cash Flow	-$2.79M	-$1.92M	-$1.59M	-$1.97M	-$3.29M
Depreciation & Amortisation	$7.22K	$7.22K	$6.76K	$5.85K	$7.20K
Stock-Based Compensation	$223.46K	$873.00	$874.00	$370.17K	$471.00K
Investing Cash Flow	$0.00	$0.00	$0.00	$0.00	-$71.88K
Financing Cash Flow	$0.00	$3.39M	$9.12M	-$41.17K	$6.70M
Net Change in Cash	-$2.79M	$1.47M	$7.53M	-$2.01M	$3.41M

Market Snapshot

About

Revelation Biosciences is a clinical-stage biotechnology company developing therapies that modulate the innate immune system. The company focuses on treatments for allergic and inflammatory diseases, with candidates targeting conditions like allergic conjunctivitis and atopic dermatitis. Revelation aims to provide alternatives to traditional immunosuppressive therapies.